Brokerages Set Baxter International Inc. (NYSE:BAX) Target Price at $22.45

Shares of Baxter International Inc. (NYSE:BAX) have been given an average rating of “Hold” by the thirteen ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $22.4545.

A number of research analysts recently issued reports on the stock. TD Cowen lifted their price target on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, July 27th. Citigroup raised shares of Baxter International from a “sell” rating to a “neutral” rating and increased their price objective for the company from $17.00 to $28.00 in a research report on Friday, July 31st. Weiss Ratings raised shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Zacks Research upgraded shares of Baxter International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, The Goldman Sachs Group increased their target price on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th.

Institutional Investors Weigh In On Baxter International

Several hedge funds and other institutional investors have recently made changes to their positions in BAX. Pzena Investment Management LLC acquired a new stake in Baxter International during the 2nd quarter worth $1,392,098,000. Tocqueville Asset Management L.P. acquired a new position in Baxter International in the second quarter valued at $30,604,000. BlackRock Inc. purchased a new position in shares of Baxter International during the second quarter worth about $1,744,874,000. AMG National Trust Bank purchased a new position in shares of Baxter International during the second quarter worth about $2,522,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Baxter International during the second quarter worth about $51,958,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Stock Down 0.1%

Shares of NYSE BAX opened at $25.81 on Friday. The stock has a market cap of $13.34 billion, a P/E ratio of -12.47, a PEG ratio of 3.91 and a beta of 0.60. The business’s fifty day simple moving average is $24.80 and its 200-day simple moving average is $20.76. Baxter International has a 12-month low of $15.73 and a 12-month high of $30.00. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 1.39.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.80 billion. During the same period in the previous year, the firm posted $0.59 EPS. Baxter International’s revenue for the quarter was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities analysts predict that Baxter International will post 2.04 EPS for the current fiscal year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s dividend payout ratio is currently -1.93%.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.